表紙
市場調査レポート

胃癌の疫学的予測 〜2024年

EpiCast Report: Gastric Cancer - Epidemiology Forecast to 2024

発行 GlobalData 商品コード 345022
出版日 ページ情報 英文 65 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
胃癌の疫学的予測 〜2024年 EpiCast Report: Gastric Cancer - Epidemiology Forecast to 2024
出版日: 2015年10月07日 ページ情報: 英文 65 Pages
概要

2014年、8大市場における胃癌発症件数は312,520件となりました。今後2024年までCAGR1.66%で拡大し、364,518件になると予測されています。中国の都市部が最大数ですが、2024年までに177,015件となる見込みです。

当レポートでは、胃癌市場について調査し、胃癌の概要と8大市場(米国、フランス、ドイツ、イタリア、スペイン、英国、日本、中国)における過去10年間の疫学的動向、国別、性別、年齢別、診断時の病期別の予測をまとめています。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • リスクファクターと併存疾患
  • 世界的動向
    • 8大市場の発症動向
  • 予測方法
    • 用いられる情報源
    • 用いられない情報源
    • 仮説と予測方法:診断件数
    • 5か年動向
    • 臨床段階別
    • 細胞別
    • HER2別
    • GEJ癌別
    • 腺癌件数
  • 胃癌の疫学的予測
    • 診断済み発症件数
    • 年齢別発症件数
    • 性別
    • 年齢標準化による発症件数
    • 病期別
    • 細胞別
    • HER2別
    • GEJ癌発症件数
    • 5年間の動向
  • 考察
    • 疫学的予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

  • 参考文献
  • 著者について
  • GlobalDataについて
  • EpiCastについて
  • 免責事項

図表

目次
Product Code: GDHCER092-15

Gastric cancer, also called stomach cancer, is a multifactorial disease that starts in the tissues lining the stomach. Gastric cancer usually begins in cells in the inner layer of the stomach and tends to develop slowly into the outer layer over many years. In the early stages of gastric cancer, the affected individuals exhibit symptoms such as indigestion and stomach discomfort that require little medical attention and therefore, most of the cases remain undetected at the initial stages of the disease. Gastric cancer typically affects elderly individuals, ages 55 years and older, and peaks in the seventh decade of life and is twice as common in men as in women.

In 2014, there were a total of 312,520 diagnosed incident cases of gastric cancer in the 8MM. GlobalData epidemiologists forecast that the diagnosed incident cases of gastric cancer in the 8MM will increase to 364,518 cases by 2024 at an Annual Growth Rate (AGR) of 1.66%. In the 8MM, urban China had the highest number of diagnosed incident cases (134,968 cases) in 2014, and is expected to grow to 177,015 cases by 2024 at a high AGR of 3.12%.

GlobalData epidemiologists' forecast for gastric cancer is supported by at least 10 years of historical data obtained from international cancer organizations, country-specific government sources, and peer-reviewed studies. The forecast of incident gastric cancer cases were based on detailed age-specific and sex-specific trends in incidence in each of the 8MM. This forecast provides detailed case-segmentation of the gastric cancer patient pool for each country by age, sex, and stage at diagnosis. Additionally, GlobalData's analysis provides diagnosed incident cases of GEJ cancer and segmentation of diagnosed gastric cancer incident cases by cellular type and HER2 status. The forecast is driven by a thorough analysis of historical data. The forecast methodology was also consistent across all the 8MM, thereby allowing for a meaningful comparison of the forecast diagnosed incident and five-year diagnosed prevalent cases of gastric cancer across the 8MM.

Scope

  • The Gastric Cancer EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for gastric cancer in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China). It includes a 10-year epidemiological forecast of the diagnosed incident cases of gastric cancer, gastroesophageal junction cancer, gastric adenocarcinoma, and the five-year diagnosed prevalent cases of gastric cancer segmented by age and sex in these markets. In addition this report provides further segmentation of gastric cancer by stage at diagnosis, cellular type, and human epidermal growth factor receptor status.
  • The gastric cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The Gastric Cancer EpiCast series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global gastric cancer market.
  • Quantify patient populations in the global gastric cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for gastric cancer therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. 8MM, Incidence Trends
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods, Diagnosed Incident Cases of Gastric Cancer - 8MM
    • 3.4.4. Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases of Gastric Cancer - 8MM
    • 3.4.5. Forecast Assumptions and Methods, Gastric Cancer Clinical Stages at Diagnosis - 8MM
    • 3.4.6. Forecast Assumptions and Methods, Gastric Cancer Cellular Types - 8MM
    • 3.4.7. Forecast Assumptions and Methods, HER2 Status - 8MM
    • 3.4.8. Forecast Assumptions and Methods, Diagnosed Incident Cases of GEJ Cancer - 8MM
    • 3.4.9. Forecast Assumptions and Methods, Diagnosed Incident Cases of Gastric Adenocarcinomas - 8MM
  • 3.5. Epidemiological Forecast of Gastric Cancer (2014-2024)
    • 3.5.1. Diagnosed Incident Cases of Gastric Cancer
    • 3.5.2. Age-Specific Diagnosed Incident Cases of Gastric Cancer
    • 3.5.3. Sex-Specific Diagnosed Incident Cases of Gastric Cancer
    • 3.5.4. Age-Standardized Diagnosed Incidence of Gastric Cancer
    • 3.5.5. Percentage Distribution of Diagnosed Incident Cases of Gastric Cancer, by Stage at Diagnosis
    • 3.5.6. Percentage Distribution of Diagnosed Incident Cases of Gastric Cancer, by Cellular Type
    • 3.5.7. Diagnosed Incident Cases of Gastric Cancer by HER2 Status
    • 3.5.8. Diagnosed Incident Cases of GEJ Cancer
    • 3.5.9. Five-Year Diagnosed Prevalent Cases of Gastric Cancer
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Gastric Cancer
  • Table 2: 8MM, Sources of Gastric Cancer Incidence Data
  • Table 3: 8MM, Sources Used in the Epidemiology Forecast for the Five-Year Diagnosed Prevalent Cases of Gastric Cancer
  • Table 4: 8MM, Sources of Gastric Cancer Stage at Diagnosis According to AJCC, TNM (Tumor, Node, Metastasis) Staging Manual
  • Table 5: 8MM, Sources of Distribution of Gastric Cancer Cases at Diagnosis by Cellular Type
  • Table 6: 8MM, Sources of GEJ Cancer Incidence Data
  • Table 7: 8MM, Sources of HER2-Positive Status in Diagnosed Incident Cases of Gastric Cancer
  • Table 8: 8MM, Diagnosed Incident Cases of Gastric Cancer, Both Sexes, Ages ≥20 Years, N, 2014-2024
  • Table 9: 8MM, Age-Specific Diagnosed Incident Cases of Gastric Cancer, Both Sexes, N (Row %), 2014
  • Table 10: 8MM, Sex-Specific Diagnosed Incident Cases of Gastric Cancer, Ages ≥20 Years, N (Row %), 2014
  • Table 11: 8MM, Diagnosed Incident Cases of Gastric Cancer, by HER2 Status, Both Sexes, Ages ≥20 Years, N (Row %), 2014
  • Table 12: 8MM, Diagnosed Incident Cases of GEJ Cancer, Both Sexes, Ages ≥20 Years, N, 2014-2024
  • Table 13: 8MM, Five-Year Diagnosed Prevalent Cases of Gastric Cancer, Both Sexes, Ages ≥20 Years, N, 2014-2024

List of Figures

  • Figure 1: 8MM, Age-Adjusted Gastric Cancer Incidence (Cases per 100,000 Population), Men, 1998-2007
  • Figure 2: 8MM, Age-Adjusted Gastric Cancer Incidence (Cases per 100,000 Population), Women, 1998-2007
  • Figure 3: 8MM, Diagnosed Incident Cases of Gastric Cancer, Both Sexes, Ages ≥20 Years, N, 2014-2024
  • Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of Gastric Cancer, Both Sexes, N, 2014
  • Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of Gastric Cancer, Ages ≥20 Years, 2014
  • Figure 6: 8MM, Age-Standardized Diagnosed Incidence of Gastric Cancer (Cases per 100,000 Population), Ages ≥20 Years, by Sex, 2014
  • Figure 7: 8MM, Percentage Distribution of Diagnosed Incident Cases of Gastric Cancer, by Stage at Diagnosis, Both Sexes, Ages ≥20 Years
  • Figure 8: 8MM, Percentage Distribution of Diagnosed Incident Cases Gastric Cancer, by Cellular Type, Both Sexes, Ages ≥20 Years
  • Figure 9: 8MM, Diagnosed Incident Cases of Gastric Cancer, by HER2 Status, Both Sexes, Ages ≥20 Years, %, 2014
  • Figure 10: 8MM, Diagnosed Incident Cases of GEJ Cancer, Both Sexes, Ages ≥20 Years, N, 2014-2024
  • Figure 11: 8MM, Five-Year Diagnosed Prevalent Cases of Gastric Cancer, Both Sexes, Ages ≥20 Years, N, 2014-2024
Back to Top